Your browser doesn't support javascript.
Third primary SARS-CoV-2 mRNA vaccines enhance antibody responses in most patients with haematological malignancies.
Cook, Lucy B; O'Dell, Gillian; Vourvou, Eleni; Palanicawandar, Renuka; Marks, Sasha; Milojkovic, Dragana; Apperley, Jane F; Loaiza, Sandra; Claudiani, Simone; Bua, Marco; Hockings, Catherine; Macdonald, Donald; Chaidos, Aris; Pavlu, Jiri; Cooper, Nichola; Fidler, Sarah; Randell, Paul; Innes, Andrew J.
  • Cook LB; Centre for Haematology, Faculty of Medicine, Department of Immunology and Inflammation, Imperial College London, London, UK.
  • O'Dell G; Department of Haematology, Hammersmith Hospital, Imperial College Healthcare NHS Trust, London, UK.
  • Vourvou E; Department of Haematology, Hammersmith Hospital, Imperial College Healthcare NHS Trust, London, UK.
  • Palanicawandar R; Department of Haematology, Hammersmith Hospital, Imperial College Healthcare NHS Trust, London, UK.
  • Marks S; Department of Haematology, Hammersmith Hospital, Imperial College Healthcare NHS Trust, London, UK.
  • Milojkovic D; Department of Haematology, Hammersmith Hospital, Imperial College Healthcare NHS Trust, London, UK.
  • Apperley JF; Centre for Haematology, Faculty of Medicine, Department of Immunology and Inflammation, Imperial College London, London, UK.
  • Loaiza S; Department of Haematology, Hammersmith Hospital, Imperial College Healthcare NHS Trust, London, UK.
  • Claudiani S; Centre for Haematology, Faculty of Medicine, Department of Immunology and Inflammation, Imperial College London, London, UK.
  • Bua M; Department of Haematology, Hammersmith Hospital, Imperial College Healthcare NHS Trust, London, UK.
  • Hockings C; Department of Haematology, Hammersmith Hospital, Imperial College Healthcare NHS Trust, London, UK.
  • Macdonald D; Department of Haematology, Hammersmith Hospital, Imperial College Healthcare NHS Trust, London, UK.
  • Chaidos A; Department of Haematology, Hammersmith Hospital, Imperial College Healthcare NHS Trust, London, UK.
  • Pavlu J; Department of Haematology, Hammersmith Hospital, Imperial College Healthcare NHS Trust, London, UK.
  • Cooper N; Centre for Haematology, Faculty of Medicine, Department of Immunology and Inflammation, Imperial College London, London, UK.
  • Fidler S; Department of Haematology, Hammersmith Hospital, Imperial College Healthcare NHS Trust, London, UK.
  • Randell P; Centre for Haematology, Faculty of Medicine, Department of Immunology and Inflammation, Imperial College London, London, UK.
  • Innes AJ; Department of Haematology, Hammersmith Hospital, Imperial College Healthcare NHS Trust, London, UK.
Nat Commun ; 13(1): 6922, 2022 Nov 14.
Article in English | MEDLINE | ID: covidwho-2119214
ABSTRACT
SARS-CoV-2 infection, and resulting disease, COVID-19, has a high mortality amongst patients with haematological malignancies. Global vaccine rollouts have reduced hospitalisations and deaths, but vaccine efficacy in patients with haematological malignancies is known to be reduced. The UK-strategy offered a third, mRNA-based, vaccine as an extension to the primary course in these patients. The MARCH database is a retrospective observational study of serological responses in patients with blood disorders. Here we present data on 381 patients with haematological malignancies. By comparison with healthy controls, we report suboptimal responses following two primary vaccines, with significantly enhanced responses following the third primary dose. These responses however are heterogeneous and determined by haematological malignancy sub-type and therapy. We identify a group of patients with continued suboptimal vaccine responses who may benefit from additional doses, prophylactic extended half-life neutralising monoclonal therapies (nMAB) or prompt nMAB treatment in the event of SARS-CoV-2 infection.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: Viral Vaccines / Hematologic Neoplasms / COVID-19 Type of study: Observational study / Prognostic study Topics: Vaccines Limits: Humans Language: English Journal: Nat Commun Journal subject: Biology / Science Year: 2022 Document Type: Article Affiliation country: S41467-022-34657-z

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Viral Vaccines / Hematologic Neoplasms / COVID-19 Type of study: Observational study / Prognostic study Topics: Vaccines Limits: Humans Language: English Journal: Nat Commun Journal subject: Biology / Science Year: 2022 Document Type: Article Affiliation country: S41467-022-34657-z